Geneva Advisors LLC Decreases Stake in Alexion Pharmaceuticals, Inc. (ALXN)
- Author: Zachary Reyes May 25, 2017,
May 25, 2017, 17:02
Its the same as in 2016Q3. Cypress Funds Llc sold 28,000 shares as Alexion Pharmaceuticals Inc (Call) (ALXN)'s stock declined 11.63%. 215.83 million shares or 2.26% more from 211.05 million shares in 2016Q3 were reported.
Investors who are keeping close eye on Alexion Pharmaceuticals, Inc.
Investors are on alert as Sonus Networks, Inc. (NASDAQ:ALXN). Tokio Marine Asset Management Communication holds 4,461 shares or 0.06% of its portfolio. Finally, Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Tuesday, April 18th. (NASDAQ:ALXN) for 12 shares. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a research report released on Tuesday morning. Calvert Invest Management owns 13,382 shares for 0.06% of their portfolio. Reliance Of Delaware owns 9,266 shares. Pension Service invested in 165,686 shares. Sei Company reported 342,705 shares. The company was maintained on Thursday, February 4 by Barclays Capital. 1,660 were accumulated by Atalanta Sosnoff Cap Ltd Liability. (NASDAQ:ALXN). Global X Limited Liability Com stated it has 1,514 shares. Hedge funds and other institutional investors own 94.98% of the company's stock.
Since November 14, 2016, it had 0 insider buys, and 27 selling transactions for $14.61 million activity. 165 shares were sold by Thiel Carsten, worth $20,739 on Monday, February 6. MACKAY MARTIN sold $27,524 worth of Alexion Pharmaceuticals, Inc. Wagner Heidi L sold 1,932 shares worth $243,371. Independent Portfolio Consultants Inc. raised its position in Alexion Pharmaceuticals by 46.9% in the first quarter. The insider Moriarty John B sold $237,516. Tekla Capital Management Llc bought 31,900 shares as the company's stock declined 11.63% while stock markets rallied.
If we look at stock performance in last active day trading, we see that stock has moved climbs 1.27% to end the day at $67.52. During the same quarter in the previous year, the company earned $1.11 earnings per share. (NASDAQ:ALXN) was up 1.39% at $115.42 on Monday, in a 52-week range of $109.12 to $157.02 and with a consensus analyst target price of $159.89. The stock was sold at an average price of $131.96, for a total value of $524,936.88. It has underperformed by 34.82% the S&P500. $351,304 worth of Alexion Pharmaceuticals, Inc. The company had revenue of $870 million during the quarter, compared to analyst estimates of $826.63 million.
In Healthcare sector, shares of Alexion Pharmaceuticals, Inc. On average, equities analysts predict that Alexion Pharmaceuticals will post $5.31 EPS for the current fiscal year. According to the past 5 years report, the company on average reported 4.70% year-over-year EPS growth and sales growth was recorded at -0.30%.
"Anavex announced positive preclinical data for 2-73 in several neurodevelopmental disorders: Angelman, Fragile X and Rett syndromes". Alexion Pharmaceuticals Inc. has $180 highest and $138 lowest target. $177.44's average target is 70.78% above currents $103.9 stock price. Alexion Pharmaceuticals Inc. had 5 analyst reports since February 17, 2017 according to SRatingsIntel.
Based on the latest notes released to investors, 8 analysts have issued a rating of "buy", 9 analysts "outperform", 4 analysts "hold", 0 analysts "underperform" and 0 analysts "sell". Finally, Credit Suisse Group AG reaffirmed a buy rating and set a $160.00 target price on shares of Alexion Pharmaceuticals in a research report on Friday, February 17th.
There are explosive trends shaping the world of technology right now and the stocks leading those trends can be identified. Alexion Pharmaceuticals now has $20.56 billion valuation. Morgan Stanley upgraded the stock to "Overweight" rating in Friday, October 2 report. Equity research analysts have forecasted the stock level. The rating was maintained by RBC Capital Markets with "Outperform" on Thursday, December 22.
The news comes almost two months after Alexion installed Ludwig Hantson as CEO.
More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Retail Bank Of America Corporation De has invested 0.05% of its portfolio in Alexion Pharmaceuticals, Inc. The company has market cap of $23.66 billion.
"Alexion confirmed that these changes are part of the new CEO's plans to refocus the company, including program and leadership reviews, and not part of ongoing investigations or trial issues", Marai wrote, adding that the executives changes are "in line with industry norms when a new CEO joins a company".
The price/earnings ratio (P/E) is 49.69 and the forward P/E ratio stands at 15.85. The Company's products include Soliris, Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).